Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Chronic Lymphocytic Leukemia
100%
Leukemia Patients
100%
IGHV mutation
100%
Overall Survival
75%
Prognostic Factors
75%
Fluorescence in Situ Hybridization
75%
Lymphocyte Doubling Time
75%
Time to First Treatment
75%
ZAP-70 Expression
75%
CD38 Expression
75%
Early Disease
50%
Prognostic Marker
50%
Treatment Survival
50%
Disease Progression
25%
Immunoglobulin Genes
25%
CD38
25%
Multivariate Analysis
25%
Prognostic Value
25%
Univariate Analysis
25%
Patient's Will
25%
Working Diagnosis
25%
Treatment Strategy
25%
Fluorescence in Situ Hybridization Analysis
25%
Prognostic Impact
25%
Age at Diagnosis
25%
Diagnostic Work-up
25%
Routine Diagnostics
25%
Prognostic Power
25%
Direct Treatment
25%
Binet Stage
25%
Mutation Age
25%
Medicine and Dentistry
B-Cell Chronic Lymphocytic Leukemia
100%
Fluorescence in Situ Hybridization
100%
IGHV@
100%
Lymphocyte
75%
Overall Survival
75%
Protein Kinase ZAP 70
75%
Diseases
50%
Disease Exacerbation
25%
Multivariate Analysis
25%
Univariate Analysis
25%
Immunoglobulin Gene
25%
Biochemistry, Genetics and Molecular Biology
Fluorescence in Situ Hybridization
100%
CD38
100%
IGHV@
100%
Lymphocyte
75%
Overall Survival
75%
ZAP70
75%
Cytogenetics
25%
Multivariate Analysis
25%
Immunoglobulin Gene
25%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Lymphatic Leukemia
100%
Overall Survival
100%
Protein Kinase ZAP 70
100%
Diseases
66%
Immunoglobulin
33%
Disease Exacerbation
33%
Immunology and Microbiology
CD38
100%
Fluorescence in Situ Hybridization
100%
Lymphocyte
75%
Overall Survival
75%
Immunoglobulin Gene
25%